TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19694994

Group type: EXPERIMENTAL
Intervention: Patients receiving blood transfusions (n = 25)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Athletes (n = 127)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Nontransfused hospitalized patients (n = 39)
Number of subjects: 127
Study: 18520803

Group type: EXPERIMENTAL
Intervention: ABT‐751 200 mg daily for 21 consecutive days, followed by 7 days off drug
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ABT‐751
Number of subjects: 35
Study: 16529564

Group type: EXPERIMENTAL
Intervention: Combined therapy (pelvic floor muscle training and duloxetine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 0
Study: 12834994

Group type: EXPERIMENTAL
Intervention: Older siblings smoking
Number of subjects: 2981
Study: 11023929

Group type: EXPERIMENTAL
Intervention: t-PA
Number of subjects: 15059

Group type: EXPERIMENTAL
Intervention: r-PA
Number of subjects: 15059
Study: 8850108

Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 2231

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2231
Study: 1346745

Group type: EXPERIMENTAL
Intervention: verapamil 0.05 mg kg‐1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: verapamil 0.1 mg kg‐1
Number of subjects: 3

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: verapamil (both doses)
Number of subjects: 3
Study: 6513620

Group type: EXPERIMENTAL
Intervention: Review of audit results only
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Criteria setting and review of audit results
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no treatment) in phase 1, then received concurrent reminders in phase 2
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Criteria setting and review of audit results (previously involved in phase 1)
Number of subjects: 3
Study: 31984623

Group type: EXPERIMENTAL
Intervention: SGLT2‐i tofogliflozin (TOFO)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 30373781

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus tablets combined with quadruple therapy
Number of subjects: 526

Group type: COMPARATOR
Intervention: Quadruple therapy
Number of subjects: 526
Study: 27412146

Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: nVNS (open-label phase)
Number of subjects: 59
Study: 25233647

Group type: EXPERIMENTAL
Intervention: Guan's quadruple therapy for kidney disease
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional western medication
Number of subjects: 80
Study: 22622628

Group type: EXPERIMENTAL
Intervention: Methylphenidate administered for one week
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 19935427

Group type: EXPERIMENTAL
Intervention: Motivationally enhanced cardiac rehabilitation (CR)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation (CR)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combined study group (both CR types)
Number of subjects: 91
Study: 18666804

Group type: EXPERIMENTAL
Intervention: FDC tablet of repaglinide/metformin 2 mg/500 mg
Number of subjects: 93
Study: 16883914

Group type: EXPERIMENTAL
Intervention: Radix Astragali Injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine treatment (control)
Number of subjects: 80
Study: 12860338

Group type: EXPERIMENTAL
Intervention: hCG bioactive/hCG immunoactive ratio
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Serum progesterone
Number of subjects: 36
Study: 10938212

Group type: EXPERIMENTAL
Intervention: Culturally sensitive program for parent-child communication, including information about tobacco and alcohol effects, social skills training, and parent-child communication skills development.
Number of subjects: 660

Group type: COMPARATOR
Intervention: Culturally sensitive program for parent-child communication
Number of subjects: 660
Study: 8828744

Group type: EXPERIMENTAL
Intervention: Higher-dose didanosine (750 mg per day for patients > or = 60 kg)
Number of subjects: 1775

Group type: COMPARATOR
Intervention: Lower-dose didanosine (200 mg per day)
Number of subjects: 1775

Group type: EXPERIMENTAL
Intervention: Higher-dose didanosine
Number of subjects: 1775

Group type: COMPARATOR
Intervention: Lower-dose didanosine
Number of subjects: 1775
Study: 1601535

Group type: EXPERIMENTAL
Intervention: Single-dose study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-dose study
Number of subjects: 0
Study: 3933861

Group type: EXPERIMENTAL
Intervention: Pirenzepine (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pirenzepine (20 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pirenzepine (30 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pirenzepine (40 mg)
Number of subjects: 6
Study: 30385613

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 295

Group type: COMPARATOR
Intervention: Sorafenib and placebo
Number of subjects: 295
Study: 31223014

Group type: EXPERIMENTAL
Intervention: Management model and safe practice from 2005-2016 including emergency diagnostic procedures, colour-Doppler, arteriography, emergency surgery (embolectomy by Fogharty and if necessary, vascular by-pass)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment method from 2000-2005
Number of subjects: 100
Study: 28028723

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) treatment (100 mL/24 h)
Number of subjects: 60
Study: 25576680

Group type: EXPERIMENTAL
Intervention: <2 g sodium diet education
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: <2 g sodium diet education (2 samples)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Male sex and higher BMI
Number of subjects: 305
Study: 23364361

Group type: EXPERIMENTAL
Intervention: Sedative instrumental music (60-80 beats per minute)
Number of subjects: 120
Study: 21742306

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conjunctival autograft
Number of subjects: 42
Study: 19919714

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in small airway epithelium
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in alveolar macrophages
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Pathway analysis of airway epithelium
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Pathway analysis of alveolar macrophages
Number of subjects: 155
Study: 16922700

Group type: EXPERIMENTAL
Intervention: X-PERT Programme (n = 157)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (individual appointments, n = 157)
Number of subjects: 314
Study: 15130591

Group type: EXPERIMENTAL
Intervention: Counting circles
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Counting emotional scenes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Emotional stimuli
Number of subjects: 22

Group type: COMPARATOR
Intervention: Neutral stimuli
Number of subjects: 22
Study: 11780705

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored nutrition education
Number of subjects: 0

Group type: COMPARATOR
Intervention: General nutrition information (Control)
Number of subjects: 0
Study: 9416888

Group type: EXPERIMENTAL
Intervention: Lisinopril (2.5 to 5 up to 10 mg/d) with or without nitroglycerin (5 to 20 microg I.V. then 10 mg/d)
Number of subjects: 2790
Study: 8269890

Group type: EXPERIMENTAL
Intervention: Vegan diet (uncooked 'living food') for 3 months, tutored daily by a living-food expert.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (usual diet, no tutoring).
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Vegan diet group.
Number of subjects: 43
Study: 3114203

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) 500 micrograms
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 29477629

Group type: EXPERIMENTAL
Intervention: Low-literacy version of the Medicaid Sterilization Consent Form
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard version of the Medicaid Sterilization Consent Form
Number of subjects: 200
Study: 26438785

Group type: EXPERIMENTAL
Intervention: Ultrasound examination of pleural cavities and inferior vena cava (IVC) by nurses
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard clinical examination without ultrasound
Number of subjects: 62
Study: 24005959

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (RT) for 12 weeks, 3 times per week (n=28)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (12 weeks of no training, n=8)
Number of subjects: 36
Study: 23671022

Group type: EXPERIMENTAL
Intervention: Coffee 6 (6 mg caffeine/kg body weight)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Coffee 3 (3 mg caffeine/kg body weight)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Water
Number of subjects: 33
Study: 19131132

Group type: EXPERIMENTAL
Intervention: G‐CSF (10 microg/kg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 18199394

Group type: EXPERIMENTAL
Intervention: Dopamine (DA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 16
Study: 16893641

Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy (5‐fluorouracil (5‐FU) 500 mg/m2/d continuous infusion for 4 cycles and vinorelbine 25 mg/m2 on specific days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy
Number of subjects: 60
Study: 14705688

Group type: EXPERIMENTAL
Intervention: Deep removal of the LMA
Number of subjects: 196

Group type: COMPARATOR
Intervention: Awake removal of the LMA
Number of subjects: 196
Study: 11293237

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg i.v. monthly
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 46
Study: 8864319

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg given twice daily for 28 days
Number of subjects: 27
Study: 1735313

Group type: EXPERIMENTAL
Intervention: PSK (oral) for over three years, mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) for over six months.
Number of subjects: 448

Group type: COMPARATOR
Intervention: Mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) for over six months.
Number of subjects: 448
Study: 6122188

Group type: EXPERIMENTAL
Intervention: Diazepam (7.5 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lorazepam (3.0 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 30420479

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily) with artemether-lumefantrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily) with artesunate-amodiaquine
Number of subjects: 0
Study: 28971551

Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised strength training (n=50)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised Nordic Walking (n=50)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Unsupervised home-based exercise (n=52)
Number of subjects: 152
Study: 26966119

Group type: EXPERIMENTAL
Intervention: 0.5 mg of DAR-0100A
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 15 mg of DAR-0100A
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 49
Study: 24574549

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over left dorsolateral prefrontal cortex for 20 minutes
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 55
Study: 18758805

Group type: EXPERIMENTAL
Intervention: Diet/3 days per week resistance training (WLRT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Diet (WL)
Number of subjects: 67
Study: 15251155

Group type: EXPERIMENTAL
Intervention: Double-reading arm (oncologist and radiologist independently interpreting radiographs)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Single-reading arm (interpretation by an oncologist only)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 869
Study: 11722957

Group type: EXPERIMENTAL
Intervention: Excess dietary cysteine (21 mg x kg(‐1) x d(‐1))
Number of subjects: 6

Group type: COMPARATOR
Intervention: No exogenous cysteine
Number of subjects: 6
Study: 9135425

Group type: EXPERIMENTAL
Intervention: Textured silicone gel-filled implants
Number of subjects: 49

Group type: COMPARATOR
Intervention: Smooth silicone gel-filled implants
Number of subjects: 49
Study: 8189476

Group type: EXPERIMENTAL
Intervention: rhGH (0.15 mg/kg/day, Somatropin, Genentech, Inc.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle of infusion (Control)
Number of subjects: 20
Study: 3555687

Group type: EXPERIMENTAL
Intervention: Single-dose cefotaxime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-dose cephradine
Number of subjects: 0
Study: 11483273

Group type: EXPERIMENTAL
Intervention: MMR at 12 months of age
Number of subjects: 937

Group type: COMPARATOR
Intervention: Revaccination with MMR at 15 months of age
Number of subjects: 937

Group type: COMPARATOR
Intervention: MV at 9 months followed by MMR at 15 months
Number of subjects: 937
Study: 31297582

Group type: EXPERIMENTAL
Intervention: Topical steroids (Group T, n: 42)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Systemic steroids (0.8 mg/kg/day peroral, Group S, n: 42)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Combined steroids (0.4 mg/kg/day peroral + topical, Group C, n: 40)
Number of subjects: 124
Study: 28891198

Group type: EXPERIMENTAL
Intervention: Targeted medical nutrition (TMN) - 230 kcal; 2 g omega-3 fatty acids; 10 μg 25-hydroxy-vitamin D3, administered twice daily for 12 weeks.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Isocaloric comparator, administered twice daily for 12 weeks.
Number of subjects: 45
Study: 28273329

Group type: EXPERIMENTAL
Intervention: Paper mode of administration
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Electronic mode of administration
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Mixed-mode administration
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Standardized self-report instruments
Number of subjects: 201
Study: 25354927

Group type: EXPERIMENTAL
Intervention: Web-based behavioral activation intervention (Bounce Back Now); specific dosage and duration not mentioned.
Number of subjects: 2024
Study: 22490629

Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (double maintenance dose of clopidogrel 150 mg/d and aspirin 300 mg/d, followed by cilostazol 50-100 mg bid if HPR persists)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Standard antiplatelet therapy (aspirin 300 mg/d and clopidogrel 75 mg/d)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy
Number of subjects: 840

Group type: COMPARATOR
Intervention: Standard antiplatelet therapy
Number of subjects: 840
Study: 19436934

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study: 17697904

Group type: EXPERIMENTAL
Intervention: LID 40 mg + MET 5 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: LID 40 mg + MET 10 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: LID 40 mg + MET 2.5 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: LID + saline
Number of subjects: 240
Study: 15716194

Group type: EXPERIMENTAL
Intervention: Flexible fluorescence cystoscopy (FFC) with hexaminolevulinate (HAL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rigid fluorescence cystoscopy (RFC) with hexaminolevulinate (HAL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rigid white light cystoscopy (RWLC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall fluorescence intensity using FFC
Number of subjects: 20
Study: 12229134

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no BIS monitoring)
Number of subjects: 60
Study: 10081301

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 9014
Study: 8613305

Group type: EXPERIMENTAL
Intervention: GOI method (Indian modification)
Number of subjects: 5

Group type: COMPARATOR
Intervention: WHO method
Number of subjects: 5
Study: 1693007

Group type: EXPERIMENTAL
Intervention: Eosine and an antiseptic (Chlorhexidine or PVP iodine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine or PVP iodine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dakin solution after 15 days of inefficacy of previous antiseptics
Number of subjects: 0
Study: 7281085

Group type: EXPERIMENTAL
Intervention: Radiotherapy with chemotherapy (adriamycin and 5-fluorouracil)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 82
Study: 31446893

Group type: EXPERIMENTAL
Intervention: Waivered physicians (n=40)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-waivered physicians (n=15)
Number of subjects: 55
Study: 28755866

Group type: EXPERIMENTAL
Intervention: Titanium brackets with fluorine protection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Titanium brackets without fluorine protection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stainless-steel brackets with fluorine protection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stainless-steel brackets without fluorine protection
Number of subjects: 30
Study: 25249430

Group type: EXPERIMENTAL
Intervention: Fiber-optic bronchoscope-guided intubation with lingual traction
Number of subjects: 91

Group type: COMPARATOR
Intervention: Fiber-optic bronchoscope-guided intubation alone
Number of subjects: 91
Study: 23252583

Group type: EXPERIMENTAL
Intervention: Piroxicam + Low-level laser therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo laser + Piroxicam
Number of subjects: 32

Group type: COMPARATOR
Intervention: Laser + Placebo Piroxicam
Number of subjects: 32
Study: 22233396

Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Flunarizine plus Topiramate
Number of subjects: 150
Study: 19240603

Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control
Number of subjects: 91
Study: 17296530

Group type: EXPERIMENTAL
Intervention: Alicaforsen
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 15377583

Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg kg(‐1) loading dose followed by 0.05 mg kg(‐1) min(‐1) infusion)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 97
Study: 11427837

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9951756

Group type: EXPERIMENTAL
Intervention: Pulse oximetry and capnography
Number of subjects: 113

Group type: COMPARATOR
Intervention: No access to pulse oximetry and capnography
Number of subjects: 113
Study: 8026260

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice a day plus amoxicillin 1 g twice a day (group I, N = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice a day plus amoxicillin 1 g twice a day (group II, N = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice a day plus amoxicillin 1 g three times a day (group III, N = 30)
Number of subjects: 90
Study: 2574836

Group type: EXPERIMENTAL
Intervention: Atracurium (initial bolus 0.5 mg/kg, continuous infusion 5.5 micrograms/kg/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vecuronium (initial bolus 0.08 mg/kg, continuous infusion 0.9 micrograms/kg/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atracurium with prostigmin (0.04 mg/kg) in recovery phase
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vecuronium with prostigmin (0.04 mg/kg) in recovery phase
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atracurium and Vecuronium (both groups)
Number of subjects: 60
Study: 31996926

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration continuous renal replacement therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study: 31178155

Group type: EXPERIMENTAL
Intervention: 12 months of adjuvant trastuzumab
Number of subjects: 3384

Group type: COMPARATOR
Intervention: 6 months of adjuvant trastuzumab
Number of subjects: 3384
Study: 28215362

Group type: EXPERIMENTAL
Intervention: 50 mg sirukumab every 4 weeks
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: 100 mg sirukumab every 2 weeks
Number of subjects: 878

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878
Study: 25082793

Group type: EXPERIMENTAL
Intervention: Very low-protein diet supplemented with amino acids and ketoacids (s-VLPD)
Number of subjects: 9610

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 9610

Group type: COMPARATOR
Intervention: Tertiary nephrology care (TNC)
Number of subjects: 9610
Study: 22568388

Group type: EXPERIMENTAL
Intervention: Educational multimedia campaign
Number of subjects: 2014
Study: 21624226

Group type: EXPERIMENTAL
Intervention: DTI and MRS examination in VCI group
Number of subjects: 52

Group type: COMPARATOR
Intervention: DTI and MRS examination in control group
Number of subjects: 52
Study: 18452749

Group type: EXPERIMENTAL
Intervention: Motor point injection technique with 60U of BTX‐A (Botox) in 2.4mL or 30U BTX‐A in 1.2mL of saline
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Multisite distributed injection technique with 90U of BTX‐A in 3.6mL
Number of subjects: 31
Study: 17181386

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 0
Study: 12698647

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous injection of Irinotekan (group 1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intraarterial regional injection of Irinotekan (group 2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intraarterial therapy with Irinotekan (group 3)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Systemic intravenous therapy with Irinotekan (group 4)
Number of subjects: 47